scholarly journals Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer

2018 ◽  
Author(s):  
Akira Tanaka ◽  
Sotaro Sadahiro ◽  
Toshiyuki Suzuki ◽  
Kazutake Okada ◽  
Gota Saito ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Metastatic Colorectal Cancer ◽  
Chemotherapy Regimen ◽  
Third Line

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Small Proportion ◽  
Biomarker Testing ◽  
Over Time

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.

scholarly journals The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)

2018 ◽  
Vol 29 ◽  
pp. viii157
Author(s):  
H. Kamiyama ◽  
Y. Yoshida ◽  
H. Yoshida ◽  
C. Kosugi ◽  
K. Ishibashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
The Third ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis

2019 ◽  
Author(s):  
Li-Na Zhou ◽  
Li-Qiang Weng ◽  
Chun-Xia Feng ◽  
Yan Zhang ◽  
Ping Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Platelet Count ◽  
Liver Fibrosis ◽  
Metastatic Colorectal Cancer ◽  
Medical Records ◽  
Chemotherapy Regimen ◽  
Splenic Enlargement ◽  
History Of ◽  
Colorectal Cancer Patients ◽  
The Impact

Abstract Background: People suffer from schistosomiasis, leading to liver fibrosis, splenomegaly and thrombocytopenia. The effects of bevacizumab plus oxaliplatin or irinotecan-based chemotherapy regimens on platelets are different, but have not been determined. We conducted a retrospective analysis in metastatic colorectal cancer (mCRC) patients evaluating the impact of bevacizumab on platelet, in order to find a more suitable plan for mCRC patients with a history of schistosomiasis.Methods: The medical records of all mCRC patients with a history of schistosomiasis who received FOLFOX or FOLFIRI with or without bevacizumab from September 1, 2017 to June 30, 2019 in Kunshan Hospital were reviewed. Platelet counts and spleen sizes were compared from the first cycle until completion of chemotherapy.Results: Evaluable splenic enlargement and thrombocytopenia results were obtained from 73 Bevacizumab-treated patients and 80 non-bevacizumab treated patients. In patients treated with oxaliplatin, the rates of splenic enlargement (19.5% vs. 66.7%, P=0.01) and thrombocytopenia (31.7% vs. 77.2%, P=0.02) were lower in the bevacizumab-treated cohort than that in the nonbevacizumab cohort. When stratified for irinotecan, there were no statistical differences of frequency of splenic enlargement between the two groups, however, the rates of thrombocytopenia were higher in the bevacizumab-treated cohort than that in the nonbevacizumab cohort (59.4% vs. 8.7%, P=0.01 ).Conclusion: The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for mCRC patients with a history of schistosomiasis, especially for lower platelet count patients.

scholarly journals A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-8
Author(s):  
Lydia M. Dreosti ◽  
Alicia McMaster ◽  
Rashem Mothilal
Keyword(s):  
Colorectal Cancer ◽  
South Africa ◽  
Survival Rate ◽  
Metastatic Colorectal Cancer ◽  
Chemotherapy Regimen ◽  
Stage Iv ◽  
Sensory Neuropathy ◽  
Therapeutic Management ◽  
First Line ◽  
Open Label

Oxaliplatin is a standard first-line treatment for metastatic colorectal cancer. The objectives were to document the therapeutic management of oxaliplatin in South Africa, determine the incidence and severity of sensory neuropathy, and record the 2-year survival rate. Meccelox was a prospective, noncontrolled, open label, multicentre, observational survey of adult patients with stage IV metastatic colorectal cancer treated with oxaliplatin-based chemotherapeutic regimens. The study was conducted from August 2007 to November 2011 in 29 sites in South Africa by 66 participating treating physicians. Among the 195 enrolled patients, 61% were treated with FOLFOX regimen (5-fluorouracil/folinic acid plus oxaliplatin) for an average of 12 cycles and 32% patients were treated with XELOX (capecitabine plus oxaliplatin) for an average of 6–8 cycles, with the main reason for discontinuation being completion of the preplanned prescribed regimen. In Meccelox survey, 80% of patients were treated with intent of palliation. Overall 64% of patients reported symptoms of sensory neuropathy. The 2-year survival rate was 30%. Conclusions. Patients received a specified preplanned number of chemotherapy cycles rather than being treated until disease progression or toxicity. Both the incidence of neuropathy and the 2-year survival rate were less than previous reports.

scholarly journals PCN40 A SYSTEMATIC REVIEW AND EXPLORATORY NETWORK META-ANALYSIS OF THIRD-LINE TREATMENTS FOR METASTATIC COLORECTAL CANCER

2020 ◽  
Vol 23 ◽  
pp. S30
Author(s):  
T. Walter ◽  
N.S. Hawkins ◽  
R. Pollock ◽  
F. Colaone ◽  
S. Shergill ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Metastatic Colorectal Cancer ◽  
Meta Analysis ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document